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Abstract 
Aims 
Antiplatelet therapy with aspirin and clopidogrel are recommended for 1 year 
after drug-eluting stent (DES) implantation or myocardial infarction. However, 
the discontinuation of antiplatelet therapy has become an important issue as 
recent studies have suggested a clustering of ischaemic events within 90 days of 
clopidogrel withdrawal.  The objective of this investigation was to explore the 
hypothesis that there is a transient “rebound” increase in platelet reactivity 
within three months of clopidogrel discontinuation. 
Methods and Results 
In this prospective study, platelet function was assessed in patients taking aspirin and 
clopidogrel for at least 1 year following DES implantation.  Platelet aggregation was 
measured using a modification of light transmission aggregometry in response to 
multiple concentrations of adenosine diphosphate (ADP), epinephrine, arachidonic 
acid, thrombin receptor activating peptide and, collagen.  Clopidogrel was stopped 
and platelet function was reassessed 1 week, 1 month and 3 months later.  
Thirty-two patients on dual antiplatelet therapy were recruited. Discontinuation of 
clopidogrel increased platelet aggregation to all agonists, except arachidonic acid.  
Platelet aggregation in response to ADP (2.5, 5, 10, 20 μM) and epinephrine (5, 20 
μM) was significantly increased at 1 month compared to 3 months following 
clopidogrel withdrawal.  Thus, a transient period of increased platelet reactivity to 
both ADP and epinephrine was observed 1 month after clopidogrel discontinuation. 
 Conclusions 
This study demonstrates a transient increase in platelet reactivity 1 month after 
clopidogrel withdrawal.  This phenomenon may, in part, explain the known clustering 
of thrombotic events observed after clopidogrel discontinuation.  This observation 
requires confirmation in larger populations. 
 
 
 
 
 
 
 
 
 
 Introduction 
The American College of Cardiology, American Heart Association and European 
Society of Cardiology, recommend that patients receive dual antiplatelet therapy 
for 1 year following myocardial infarction (MI) or drug-eluting stent (DES) 
revascularisation [1-3].  It is however unclear how patients should be treated 
after a year of aspirin and clopidogrel.  The discontinuation of antiplatelet 
therapy in patients with established coronary artery disease (CAD) has become 
an important issue, as epidemiological studies have suggested an increased risk 
of adverse events when clopidogrel is discontinued after a year of therapy [4, 5].  
Ho et al described a significant increase in the risk of recurrent MI and death 
within 90 days of clopidogrel cessation in 3,137 MI patients treated with 
percutaneous coronary intervention (PCI) or medical therapy [4].  The reasons 
for this clustering of ischaemic events after clopidogrel discontinuation are not 
clear, but could be related to a rebound hyperthrombotic period, possibly due to 
increased platelet reactivity [5]. 
Thrombotic complications following discontinuation of antiplatelet therapy have 
been recognised for almost a decade [6].  Indeed, aspirin withdrawal or non-
adherence has been associated with a three-fold increase in ischaemic events in 
patients with CAD [7].  More recently, the premature discontinuation of 
clopidogrel has been associated with the development of stent thrombosis 
following DES implantation [8-11]. 
Recent clinical studies have challenged the association of clopidogrel withdrawal 
and adverse clinical events [12, 13].  Moreover, conflicting results have emerged 
from studies of platelet function following clopidogrel discontinuation [14-16]. 
Lordkipanidze et al observed rebound platelet reactivity following clopidogrel 
withdrawal in patients with CAD, treated with dual antiplatelet therapy for 1 
year [14].  In contrast, Sibbing et al compared platelet aggregation in patients 
randomised to a strategy of tapered clopidogrel withdrawal to those who 
discontinued clopidogrel abruptly, and did not find any evidence of a rebound 
phenomenon in platelets [15].   
Thus, it is not clear if clopidogrel withdrawal precipitates a period of increased 
platelet reactivity in patients taking long-term dual antiplatelet therapy.  
Furthermore, there remains a paucity of data characterising platelet function 
following discontinuation of chronic clopidogrel therapy [15].  While the 
increased risk of ischaemic events following clopidogrel withdrawal is observed 
for up to 90 days, no study to date has evaluated platelet reactivity beyond 1 
month following clopidogrel discontinuation.  The objective of the present 
investigation was to explore the hypothesis that there is a transient “rebound” 
increase in platelet reactivity within three months of stopping clopidogrel 
therapy. 
Methods 
Patient population and study design. 
This study was approved by the Medical Research Ethics committee of Beaumont 
Hospital and conformed to the Declaration of Helsinki. 
Patients with stable CAD were eligible for study inclusion if they fulfilled the 
following criteria; they had undergone PCI with DES > 1 year previously; had 
been taking 75mg of both aspirin and clopidogrel for a minimum of 12 months 
following PCI and, had no contraindications to clopidogrel discontinuation.  
Patients were excluded if they were non-compliant with antiplatelet therapy; 
were taking antiplatelet drugs other than aspirin and clopidogrel (dipyridamole, 
ticlopidine), oral anticoagulants, steroidal or nonsteroidal anti-inflammatory 
drugs; had an acute cardiovascular event during the interval between PCI and 
study enrolment; a platelet count <125,000/mm3; haematocrit <25%; or active 
malignancy.  
All subjects were recruited from the cardiology out-patient department in our 
institution and underwent screening with a detailed medical history, physical 
examination and laboratory analysis, including complete blood count, serum 
electrolytes, glucose, urea and creatinine.  Compliance with antiplatelet therapy 
was assessed with a questionnaire prior to obtaining informed consent.  Platelet 
function was assessed while patients were taking both aspirin and clopidogrel.  
In all patients, the thienopyridine was stopped and platelet function testing was 
repeated 1 week, 1 month and 3 months after clopidogrel discontinuation 
(Figure 1).  Aspirin therapy was continued in all patients and alteration of other 
medical therapy was not permitted for the duration of the study.  To assess the 
degree of variability in platelet reactivity over time, we also recruited 10 patients 
with known CAD on chronic aspirin therapy to act as a control group.  These 
patients underwent platelet function testing at identical intervals to the patients 
who discontinued clopidogrel. 
Platelet Function Analysis 
Platelet function testing measures the ability of platelets to aggregate or adhere 
in response to agonists [17].  A wide variety of in vitro platelet function assays 
are available, each with considerable disadvantages [17, 18].  Light transmission 
aggregometry (LTA) is considered to be the gold standard platelet function test 
but is time consuming, labor intensive and necessitates highly skilled laboratory 
staff.  We developed a modification of LTA, which is rapid, inexpensive and is 
capable of assessing multiple platelet receptors and pathways simultaneously 
[19-23].  
Early morning phlebotomy was performed on all subjects following an overnight 
fast.  Uncuffed blood samples were drawn by a single phlebotomist from an 
antecubital vein using a 19-gauge butterfly needle and into 3.2% trisodium 
citrate, after discarding the first 5 ml of free flowing blood.  Samples were 
centrifuged for 10 minutes at 150 × g and platelet-rich plasma (PRP) supernatant 
was collected.  The PRP was not adjusted for platelet count.  
Platelet function was measured in response to 5 platelet agonists: arachidonic 
acid (AA), adenosine diphosphate (ADP), epinephrine, thrombin receptor 
activating peptide (TRAP), and collagen.  Similar to LTA, this assay measures 
light absorbance after the addition of soluble agonists to PRP.  In brief, 180 μL of 
platelet-rich plasma was added to the wells of a 96-well plate containing eight 
incremental concentrations of the agonists; arachidonic acid (500, 375, 188, 
93.8, 46.9, 23.4, 11.8, 5.86) μg mL-1; ADP and TRAP (20, 10, 5, 2.5, 1.25, 0.625, 
0.313, 0.156) μΜ; epinephrine (20, 5, 1.25, 0.313, 0.078, 0.0195, 0.00488, 
0.00122) μM; and collagen (190, 143, 71.3, 35.6, 17.8, 8.9, 4.45, 2.23) μg mL-1.  
Control wells containing saline buffer, platelet-rich and platelet-poor plasma 
were also prepared.  Light transmission was measured using a 572-nm filter at 0, 
3, 9, 15 and 18 minutes and the plate was constantly rotated at 1000 r.p.m. 
through a 1 mm orbit between measurements.  Results were converted to 
percentage platelet aggregation based on the platelet-rich and platelet-poor 
plasma absorbance values, which represented 0% and 100% aggregation 
respectively. The maximal percentage aggregation measured for each agonist-
concentration over the 18 minutes was calculated and plotted as dose-response 
curves.  Experiments were performed with a Victor 3TM Multilabel plate reader 
(Perkin Elmer, Wellesley, MA, USA). 
End Point Determination and Statistical Analysis 
The study hypothesis was that platelet reactivity would be increased at 1 month 
compared to 3 months following clopidogrel discontinuation.  We calculated that 
we needed to include at least 31 patients to detect a 10% difference in ADP (5 
µM)-induced platelet aggregation, in order to give the study a 90% power with a 
one sided alpha value of 0.05.   
Categorical variables were expressed as frequencies and percentages.  
Continuous variables were analysed for a normal distribution with the 
Kolmogorov-Smirnov test (using p value > 0.2 as threshold).  Normally 
distributed variables are presented as mean ± standard deviation. Variables that 
did not follow a normal distribution are represented as median and interquartile 
range.  The comparison of the dose-response curves (EC50) across the 4 study 
time points was performed using the extra sum-of-squares F-test.  Comparisons 
of the maximal platelet aggregation between the 3 time points following 
clopidogrel discontinuation were analysed using analysis of variance (ANOVA) 
with Bonferroni correction. The nominal level of significance was 5%.  Statistical 
analyses were performed with SPSS (version 17, SPSS Inc., Chicago, Illinois).  
 
Results 
Thirty-eight patients were screened for study inclusion between July 2008 and 
February 2009.  Six patients were excluded, 5 due to non-compliance with 
antiplatelet therapy and 1 due to an abnormal screening complete blood count.  
Finally, 32 patients (78% male) were enrolled in the study, with a mean age of 
64 ± 11 years.  The study population had a typical array of cardiovascular risk 
factors; 73% hypertension; 73% dyslipidaemia; 25% type 2 diabetes; 18% 
cigarette smokers; 41% obese (body mass index >30 kg/m2); 28% chronic renal 
impairment (glomerular filtration rate < 60 ml/min); and 63% had a prior MI.  
All patients were treated with aspirin and clopidogrel, with the majority taking 
HMG-CoA reductase inhibitors (94%), angiotensin converting enzyme-inhibitors 
(86%) and beta-receptor blockers (91%). 
Platelet function was measured on 4 separate occasions and the dose-response 
curves for each agonist are presented in Figure 2.  The pattern of recovery of 
platelet function following clopidogrel discontinuation was different for each 
agonist / signalling pathway.  For each agonist, we compared the agonist 
concentration that gave a response halfway between baseline and maximum 
platelet aggregation (EC50) at each of the 4 study time points.  The LogEC50 
values for ADP and TRAP-induced platelet aggregation were significantly 
different (p < 0.001), whereas there was no difference in the LogEC50 values for 
arachidonic acid, epinephrine or collagen (p = NS).  The comparisons of maximal 
platelet aggregation for each agonist/platelet-signalling pathway are presented 
individually below  (Table 1 & Figure 3).   
ADP-induced platelet aggregation 
Maximal platelet aggregation in response to 20 μM ADP was 43 ± 16.5% at study 
entry while patients were taking aspirin and clopidogrel.  Discontinuation of 
clopidogrel resulted in increased ADP-mediated aggregation by 1 week (63.7 ± 
8.3%).  The response to ADP increased further at 1 month (63.7 ± 8.3% vs 71.8 ± 
6.1%, p < 0.001).  By contrast, there was a significant decrease in platelet 
aggregation in response to ADP at 3 months (71.8 ± 6.1% vs 67.8 ± 5.6%, p = 
0.017).  This transient increase in ADP-induced platelet reactivity at 1 month 
was consistently observed in response to multiple concentrations of ADP (2.5, 5, 
10, 20 μM). 
Epinephrine-induced platelet aggregation 
Platelet aggregation in response to 20 μM epinephrine was 45.1 ± 13.9% while 
patients were on aspirin and clopidogrel.  Following clopidogrel withdrawal, 
aggregation in response to epinephrine increased to 51.5 ± 15.9% at 1 week, 
with a further rise to 55.9 ± 14.6% at 1 month.  Analogous to the decrease in 
platelet reactivity in response to ADP between 1 and 3 months, there was a 
significant reduction in epinephrine-induced platelet aggregation to 49 ± 16.5% 
at 3 months (p = 0.039).  This observation was consistent for both 5 μM and 20 
μM epinephrine concentrations. 
Arachidonic Acid- induced platelet aggregation 
At study entry, the maximal platelet aggregation measured in response to 500 
μg/mL-1 arachidonic acid was 2.2 ± 5.1%.  Arachidonic acid-mediated platelet 
aggregation did not change throughout the study (p = 0.99). 
TRAP- induced platelet aggregation 
Maximal platelet aggregation in response to 20 μM TRAP was 66.6 ± 12.6% at 
study entry and increased significantly following clopidogrel withdrawal.  At 1 
week, aggregation in response to TRAP had increased to 76.7 ± 5.8%, with a 
further increased to 82 ± 4.1% by 1 month (p = 0.002).  However, there was no 
significant decrease in TRAP-induced platelet aggregation between 1 and 3 
months (82 ± 4.1% vs 80.4 ± 6.2%, p = 0.816). 
Collagen- induced platelet aggregation 
At study entry, maximal platelet aggregation in response to 190 μg/mL-1 collagen 
was 72.3 ± 7.3%.  Following clopidogrel discontinuation, collagen-mediated 
platelet aggregation increased to 75.7 ± 6.9% at 1 week, with a further increase 
to 78.4 ± 10.4% at 1 month. There was no difference in platelet aggregation in 
response to collagen between 1 and 3 months (78.4 ± 10.4% vs 78.1 ± 6.9%, p = 
0.99). 
We observed considerable interindividual variability in platelet function 
following clopidogrel discontinuation.  Platelet aggregation in response to ADP 
was significantly increased at 1 month compared to 3 months in 21 patients, thus 
two thirds of our patients demonstrated a transient increase in platelet reactivity 
following clopidogrel withdrawal.  The magnitude of this increase in platelet 
aggregation to ADP (5 μM) ranged from 5.1 – 22.8% (Mean 11.5 ± 5%). In 
contrast, platelet aggregation to ADP was similar at 1 and 3 months (± 5%) in 11 
patients.  A multivariate analysis did not identify any measurable patient 
characteristic to be predictive of the increased response to ADP or epinephrine 
at 1 month. 
Discussion 
The results of this study demonstrate that platelet aggregation in response to 
ADP and epinephrine was significantly increased at 1 month compared to 3 
months after clopidogrel was discontinued.  This result was consistent for 
multiple concentrations of ADP (2.5, 5, 10, 20 μM) and epinephrine (5, 20 μM) 
and occurred in two thirds of our patient population.  Thus, our results 
demonstrate a temporal, transient increase in platelet reactivity 1 month 
following clopidogrel withdrawal. 
Increased ADP-mediated platelet aggregation is characteristic of an impaired 
response to clopidogrel and defines high on-treatment platelet reactivity in 
patients taking dual antiplatelet therapy [24].  High platelet reactivity is 
associated with an increased risk of recurrent ischaemic events and stent 
thrombosis (ST) after PCI [25-29].  Recently, it has been suggested that the 
withdrawal of long-term clopidogrel therapy may induce a period of high platelet 
reactivity and therefore increase thrombotic risk [4, 5, 30, 31]. 
Numerous clinical studies have shown that the early interruption of clopidogrel 
therapy in recipients of DES results in a marked increase in the rates of stent 
thrombosis (ST) and death [8, 10, 11].  In fact, discontinuation of dual-
antiplatelet therapy is the most powerful predictor of ST during the first 6 
months after stent implantation [32].  It is likely however, that ST in the setting 
of premature withdrawal of clopidogrel is caused by uninhibited platelet 
adhesion to both thrombogenic stents and disrupted vascular endothelium and 
is not due to rebound platelet hyperreactivity [33].  Several other factors that 
contribute to pathophysiology of ST have also been recognised, including patient 
[34], procedural [35] and, stent variables [36-38].   
Recently, Ho et al described an excess of ischaemic events and increased 
mortality within 90 days of clopidogrel discontinuation in 3,137 patients who 
suffered an acute coronary syndrome [4].  Importantly, the rates of death and MI 
were higher in the 1,568 patients treated with medical therapy compared to 
those who underwent PCI.  Thus, ischaemic events following clopidogrel 
withdrawal are not exclusively stent related.  The clustering of events following 
clopidogrel withdrawal suggests a rebound hyperthrombotic period, possibly 
due to increased platelet reactivity.  While the same authors have confirmed 
these findings in a recent follow-up analysis [5], conflicting data have also 
emerged [12, 13, 39].  A post-hoc analysis of the CHARISMA (Clopidogrel for 
High Atherothrombotic Risk and Ischemic Stabilization, Management, and 
Avoidance) trial, which compared the efficacy and safety of clopidogrel plus 
aspirin compared with aspirin alone in patients at high risk of cardiovascular 
events, did not observe a clinically detectable rebound effect [12].  Furthermore, 
a recent retrospective analysis of 2,254 patients who underwent coronary DES 
implantation only observed an increased risk of adverse events following 
clopidogrel cessation if the thienopyridine was stopped within 6 months of stent 
implantation [39]. 
Studies of platelet function following clopidogrel discontinuation have also 
reported conflicting results [14-16].  Lordkipanidze et al compared platelet 
aggregation in 37 CAD patients scheduled to discontinue clopidogel with 37 CAD 
patients taking only aspirin [14].  Platelet aggregation was measured repeatedly 
for 1 month using both VerifyNow® P2Y12  and LTA in response to multiple 
concentrations of ADP (1 – 20 µM).  There was no difference between the groups 
with the VerifyNow® P2Y12  or in response to the higher ADP (10 – 20 µM) 
concentrations, however there was a significant increase in platelet aggregation 
in response to lower ADP concentrations (1 - 5 µM) in patients who stopped 
clopidogrel.  In our study, we observed increased ADP-mediated platelet 
aggregation in response to both higher (20 – 10 µM) and lower ADP (2.5 – 5 µM) 
concentrations following clopidogrel discontinuation, though there was no 
difference at ADP concentrations < 2.5 µM.  Similar to our study, the enhanced 
platelet reactivity in response to ADP was evident 1 month after clopidogrel 
discontinuation.  
Contradictory results have been reported by Sibbing et al, who compared platelet 
aggregation in patients randomised to a strategy of tapered clopidogrel 
withdrawal (n = 35) to those who discontinued clopidogrel abruptly (n = 34) 
[15].  Platelet aggregation in response to ADP, TRAP and collagen was measured 
weekly up to 1 month following drug withdrawal using both LTA and multiple 
electrode aggregometry.  No difference in maximal platelet aggregation to ADP 
was observed up to 1 month following clopidogrel discontinuation and the 
authors concluded that there was no evidence for a rebound phenomenon in 
platelets.  However, these investigators did not measure platelet aggregation 
beyond 1 month, despite clinical evidence suggesting an increase in adverse 
events for up to 90 days following clopidogrel cessation [4, 5].  Moreover, a trend 
towards decreased ADP–mediated platelet aggregation at 3 weeks following 
clopidogrel discontinuation is evident in this data.  Based on our results, 
continued platelet function testing out to 90 days may have provided additional 
important information.  
The Platelet Activity after Clopidogrel Termination (PACT) study, a prospective, 
randomised, double-blind, placebo-controlled crossover study, measured 
platelet reactivity in 15 healthy volunteers who received dual antiplatelet 
therapy for 14 days [16].  Platelet reactivity was measured repeatedly out to 45 
days using whole blood flow cytometry and by LTA in response to both 
submaximal and maximal concentrations of ADP, TRAP and collagen.  While the 
authors found no evidence for rebound platelet reactivity, these data may not 
accurately reflect the effect of long-term clopidogrel therapy on the recovery of 
platelet function following clopidogrel cessation in a cardiovascular population.  
We observed increased platelet reactivity at 1 month following clopidogrel 
discontinuation in patients with CAD taking long-term dual antiplatelet therapy 
(mean 18 ± 3 months). 
Two thirds of our patient population demonstrated a transient increase in 
platelet reactivity 1 month following clopidogrel discontinuation.  The 
magnitude of the enhanced response to ADP (5 μM) ranged from 5.1 – 22.8% 
(Mean 11.5 ± 5%).  Given that an appropriate response to clopidogrel maybe 
defined as a 10% reduction in ADP-mediated platelet aggregation [24], the 
increase in ADP reactivity that we observed 1 month following clopidogrel 
discontinuation is considerable.  However, it is unlikely that a transient increase 
in platelet reactivity could solely account for the increased rate of ischaemic 
events described in the literature.  Other possible precipitants for these events 
following clopidogrel withdrawal may include; delayed endothelial healing with 
DES; loss of protection from dual antiplatelet therapy; endothelial dysfunction 
and increased inflammation after clopidogrel withdrawal [40, 41].  Nevertheless, 
an increase in platelet reactivity is a potential risk factor for the development of 
acute ischaemic events [42]. 
The precise mechanism for the transiently enhanced platelet aggregation we 
observed is not known.  Long-term clopidogrel therapy is associated with a 
reduction in inflammatory markers, in particular high sensitivity C-reactive 
protein and P-selectin [41, 43, 44], which are both been associated with 
ischaemic events following PCI [45, 46].  These anti-inflammatory effects appear 
to be unique to clopidogrel amongst antiplatelet agents, and may therefore be 
specifically linked to the P2Y12 receptor [43, 44, 47-51].  The abrupt 
discontinuation of clopidogrel may therefore initiate a proinflammatory milieu, 
which results in increased ADP-mediated platelet aggregation.   
A platelet rebound phenomenon would be expected to occur approximately 2 
weeks following clopidogrel discontinuation, as circulating platelets would not 
be inhibited by the active metabolite of clopidogrel.  Our observations and those 
of other investigators [14] of increased reactivity at 1 month following 
clopidogrel withdrawal are thus, difficult to explain.  It is possible that the 
inflammatory milieu induced by clopidogrel withdrawal peaks at 1 month or that 
chronic clopidogrel therapy affects the megakaryocyte, resulting in altered 
platelet function beyond the duration required for replacement of the platelet 
pool [52]. 
We observed a parallel increase in platelet aggregation in response to ADP and 
epinephrine 1 month after clopidogrel discontinuation.  Catecholamines are 
known to potentiate the effects of other platelet agonists and in particular the 
platelet α-2 adrenergic receptor contributes to high on-treatment platelet 
reactivity [53].  We have previously described a correlation between ADP- and 
epinephrine-mediated platelet aggregation in cardiovascular patients on dual 
antiplatelet therapy [19].  It is not clear why ADP and epinephrine-mediated 
platelet aggregation is linked as downstream signal transduction differs 
considerably between the Gi-coupled P2Y12 receptor and the Gz-coupled α-2 
adrenergic receptor.  Further studies are required to investigate this interaction.  
 
Study Limitations 
In this prospective study we did not measure platelet reactivity prior to or 
immediately after the initiation of clopidogrel.  This may have provided a ‘true 
baseline’ platelet reactivity for each patient however, the majority of our cohort 
had stenting in the setting of acute MI, thus early platelet function testing would 
not have accurately reflected a true baseline measurement.  As such, we elected 
to test each patient 3 months following clopidogrel cessation and believe that 
this reflects an accurate estimate of each patient’s baseline platelet reactivity.  
The precise mechanism of the unique enhanced response to ADP and 
epinephrine is unclear, but maybe due to other mechanisms of action of 
clopidogrel than the blockade of the P2Y12 receptor [41].  We did not measure 
markers of inflammation such as CRP or P-selectin, however this has been 
extensively evaluated in the setting of clopidogrel discontinuation by other 
investigators [41, 43, 49, 50].  While most of our patients demonstrated 
increased platelet reactivity 1 month following clopidogrel cessation, no 
thrombotic events occurred during the study.  Thus, we have not demonstrated a 
definitive association between increased platelet reactivity following clopidogrel 
discontinuation and recurrent ischaemic events. We measured platelet function 
at 3 predefined time points following clopidogrel discontinuation however, more 
frequent platelet function analysis may have yielded additional relevant 
information.  The results of this study are observational and require 
confirmation in larger patient populations, tested with multiple assays of platelet 
function. 
 
Conclusion 
This study demonstrates a transient increase in platelet reactivity 1 month after 
discontinuation of long-term clopidogrel therapy in a cardiovascular population. 
These findings may have clinical implications with respect to thrombotic events 
and merit further study in a larger population. 
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Figure Legends 
 
Fig 1 
Title   Study Protocol 
Legend Schematic representation of the study protocol.  
 
Fig 2 
Title Platelet function following clopidogrel discontinuation is agonist 
specific.  
Legend Platelet aggregation to increasing concentrations of arachidonic acid, 
collagen, thrombin receptor activating peptide (TRAP), adenosine 
diphosphate, and epinephrine at study entry and 1 week, 1 month and 3 
months following clopidogrel discontinuation.  Each data point 
represents mean aggregation (%) to each concentration. The p – values 
are generated using the extra sum-of-squares F-test, and represent 
the comparison of the dose-response curves (EC50) across the 4 
study time points.  *** p < 0.001.  
Fig 3 
Title Platelet aggregation in response to ADP and epinephrine is uniquely 
increased one month after clopidogrel discontinuation. 
Legend Platelet aggregation in response to selected concentrations of 
adenosine diphosphate, epinephrine, arachidonic acid, collagen, and 
TRAP at study entry and at 1 week, 1 month and 3 months following 
clopidogrel discontinuation.  Each point indicates mean platelet 
aggregation (%) with standard error of the mean. The p – values are 
calculated with analysis of variance and the Bonferroni correction. 
TRAP, thrombin receptor activating peptide.  * p < 0.05, ** p < 0.01. 
 
Supplemental Fig 1 
Title  Platelet aggregation in the control patients  
Legend Platelet aggregation in response to selected concentrations of 
adenosine diphosphate, epinephrine, arachidonic acid, collagen, and 
TRAP at study entry and at 1 week, 1 month and 3 months later.  Each 
point indicates mean platelet aggregation (%) with standard error of 
the mean. 
 Table 1. 
Platelet Function Profile Analyses 
Platelet Agonist  Study entry  1 Week  1 Month 
1 Week vs 1 
Month  1 Month  3 Months 
1 Month vs 
3Months 
Arachidonic acid 
(μg/mL‐1)        p ‐ value      p ‐ value 
500  2.2 ± 5.1  4.8 ± 6.2  6.2 ± 11.6  0.66  6.2 ± 11.6  3.4 ± 6  0.99 
Adenosine 
diphosphate (μM)               
0.313  0.2 ± 1.9  0.6 ± 2.1  1.8 ± 4.9  0.55  1.8 ± 4.9  0.7 ± 2.4  0.59 
0.625  2.1 ± 4.8  9.2 ± 9.9  13.9 ± 11.4  0.22  13.9 ± 11.4  9.1 ± 9.6  0.20 
1.25  8.4 ± 9.8  26.3 ± 14.5  33 ± 11.9  0.18  33 ± 11.9  27.2 ± 15.8  0.30 
2.5  18.2 ± 14.2  41.5 ± 12.8  47.3 ± 11.9  0.026  47.3 ± 11.9  42.1 ± 13.9  0.032 
5  30.7 ± 16.2  51.6 ± 10.4  59.7 ± 9.6  <0.001  59.7 ± 9.6  53.7 ± 9.8  0.002 
10  39.1 ± 16.7  59.5 ± 9.4  67.3 ± 7.6  <0.001  67.3 ± 7.6  62.2 ± 7.1  0.003 
20  43 ± 16.5  63.7 ± 8.3  71.8 ± 6.1  <0.001  71.8 ± 6.1  67.8 ± 5.6  0.017 
Epinephrine (μM)               
1.25  21.3 ± 11.3  21.2 ± 13.5  24.7 ± 13  0.45  24.7 ± 13  19.3 ± 15  0.125 
5  30.7 ± 14.7  34.6 ± 15.4  39.6 ± 16.5  0.09  39.6 ± 16.5  32.9 ± 15.9  0.021 
20  45.1 ± 13.9  51.5 ± 15.9  55.9 ± 14.6  0.14  55.9 ± 14.6  49 ± 16.5  0.039 
TRAP (μM)               
5  53.1 ± 18.4  68.6 ± 8.4  72.1 ± 19.9  0.84  72.1 ± 19.9  73.2 ± 7.8  0.99 
10  60.6 ± 12.3  73.5 ± 6.5  79.7 ± 4.2  <0.001  79.7 ± 4.2  77.3 ± 7.3  0.26 
20  66.6 ± 12.6  76.7 ± 5.8  82 ± 4.1  0.002  82 ± 4.1  80.4 ± 6.2  0.82 
Collagen (μg/mL‐1)               
71.3  12.5 ± 5.7  24.5 ± 20.7  23 ± 20.4  0.99  23 ± 20.4  21.9 ± 17.3  0.99 
143  57.5 ± 13.3  65.4 ± 14.9  69.9 ± 12.1  0.57  69.9 ± 12.1  73.4 ± 10.1  0.69 
190  72.3 ± 7.3  75.7 ± 6.9  78.4 ± 10.4  0.66  78.4 ± 10.4  78.1 ± 6.9  0.99 
 
Legend 
Data are expressed as mean ± SD values of percentage of platelet aggregation.  p ‐ 
values represent differences in means in platelet aggregation calculated using 
repeated measures analysis of variance with the Bonferroni correction. There 
was no difference in response to the lower concentrations of each agonist at 
these intervals, thus we present data from the higher concentrations only. TRAP, 
thrombin receptor activating peptide. 
 
 
 
